- Global Pharma News & Resources

Appointment of Chairman

London, UK, 22 January 2019: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, is pleased to announce the appointment of James Karis as non-executive Chairman of the Company with immediate effect. 


James has served on Shield’s Board of Directors for almost 3 years as a member of the Audit and Nominations Committees and as Chair of the Remuneration Committee.  A proven entrepreneur, he brings to Shield over 35 years of experience in the pharmaceutical, healthcare services, technology and medical device industries.  He is also a seasoned Board member for both public and private companies with extensive experience in corporate strategy, M&A and all aspects of company financing, particularly with respect to the US market.  Most recently he was Chief Executive Officer of the privately held MAPI Group until its sale to ICON plc in 2018 and has previously held senior management and executive roles at CollabRx, Entelos, Inc., PAREXEL International, Pharmaco International and Baxter International.


James Karis, Chairman of Shield Therapeutics, said: “It is exciting to take on an expanded role as Chairman of Shield Therapeutics during a time when the Company has several important milestones on the horizon.  I look forward to working with the rest of the Board and management team in continuing our efforts to provide a unique therapy benefiting patients around the world while making Shield a success for its shareholders.”


Carl Sterritt, CEO of Shield Therapeutics, said: “I am very pleased to see James appointed as our Chair.  The understanding of the business and the opportunity for Feraccru that he has developed over the last three years of Shield Therapeutics, combined with his extensive leadership experience and multiple exposures to licensing, mergers and acquisitions, not least in the USA, will, I am sure, prove to be of significant value to Shield’s shareholders.  I look forward to working closely with and benefitting from his counsel as we look to execute on our strategy to crystallise the significant value that exists in our excellent product portfolio.”

Editor Details

Last Updated: 22-Jan-2019